Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing